STRATEGIC ALLIANCE AGREEMENTStrategic Collaboration Agreement • April 6th, 2017 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Texas
Contract Type FiledApril 6th, 2017 Company Industry JurisdictionThis Strategic Collaboration Agreement (“Agreement”), effective as of the 23rd day of September, 2016 (“Effective Date”), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and Adaptimmune LLC, with a place of business located at 2001 Market Street, Philadelphia, PA 1903, USA (“Adaptimmune”); and Adaptimmune Limited, with a place of business at 101 Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune Limited”) (MD Anderson and Adaptimmune each a “Party” and collectively the “Parties”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between Merck Sharp & Dohme B.V., and Adaptimmune Limited Dated: October 27th, 2016Trial Collaboration and Supply Agreement • April 6th, 2017 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 6th, 2017 Company Industry JurisdictionThis CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of October 27, 2016 (the “Effective Date”), is by and between Merck Sharp & Dohme B.V., having a place of business at Waarderweg 39, 2031 BN Haarlem, Netherlands (“Merck”), and Adaptimmune Limited, having a place of business at 101 Park Drive, Milton Park, Abingdon Oxfordshire, OX14 4RY, UK (“Adaptimmune”). Merck and Adaptimmune are each referred to herein individually as “Party” and collectively as “Parties”.